Scalper1 News
Biotech Celgene (CELG) received a double dose of good news Tuesday as its drug Abraxane won a key approval in Europe, and partner Epizyme (EPZM) produced positive results on its leukemia drug. In early trading, Celgene stock was up 2%, near 165, while Epizyme’s vaulted 68% in the stock market today. The European Commission approved Abraxane combined with gemcitabine (better known as Eli Lilly’s (LLY) Gemzar) as a first-line treatment for Scalper1 News
Scalper1 News